Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMITHKLINE BECKMAN FENOLDOPAM CLINICALS IN CHRONIC HYPERTENSION HALTED

Executive Summary

SMITHKLINE BECKMAN FENOLDOPAM CLINICALS IN CHRONIC HYPERTENSION HALTED "recently" due to the lack of efficacy with the oral form of the drug, SmithKline said. The firm added that it is "aggressively pursuing worldwide development of oral fenoldopam in congestive heart failure and renal failure." The oral fenoldopam hypertension trials are being terminated in Phase III, while studies of the oral dopamine agonist/renal vasodilator in congestive heart failure and renal failure are progressing through Phase II. SmithKline added that it is continuing its "major development program" for the I.V. form of fenoldopam in the treatment of acute hypertensive emergencies and in congestive heart failure. The firm said that the drug has shown good efficacy in acute indications but not for chronic disease. Outside of Ridaura and the firm's program to expand Tagamet labeling, oral fenoldopam was the furthest along of SmithKline's research agents in the pipeline. A second dopamine agonist, ibopamine, is projected to move into Phase III trials this year. SmithKline continues to gear up for approval of Ridaura, the oral gold compound expected sometime this year. The company's first internal sales promotion for Ridaura reportedly took place the last week of April in Philadelphia. The Ridaura NDA has been reviewed twice by FDA's Arthritis Drugs Advisory Cmte.: in January 1982 the panel recommended approval of the drug for remission of rheumatoid arthritis; and more recently, in October 1984, the panel reviewed additional clinical data and discussed labeling of the compound.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel